BSE – Pratt School of Engineering, Duke University, Durham, North Carolina
MD – Mayo Medical School, Rochester, Minnesota
PhD – Mayo Graduate School, Rochester, Minnesota
- Intratumoral heterogeneity within pediatric solid tumors
- Mechanisms of recurrence in soft tissue sarcomas
- Novel drug treatments for pediatric sarcomas
Pratz KW, Koh B, Patel AG, Flatten KS, Poh W, Herman J, Dilley R, Harrell MI, Smith BD, Karp JE, Swisher EM, McDermitt MA, Kaufmann SH. Poly(ADP-ribose) polymerase inhibitor hypersensitivity in aggressive myeloproliferative neoplasms. Clin Cancer Res 22:3894-3902, 2016.
Patel AG*, Flatten KS*, Peterson KL, Beito TG, Schneider PS, Perkins AL, Harki DA, Kaufmann SH. Immunodetection of human topoisomerase I-DNA covalent complexes. Nucleic Acids Res 44:2816-2826, 2016. *Co-first authors
Patel AG*, De Lorenzo S*, Flatten KS*, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro. Clin Cancer Res 18(6):1655-1662, 2012. *Co-first authors
Patel AG, Flatten KS, Schneider PA, Dai NT, McDonald JS, Poirier GG, Kaufmann SH. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. J Biol Chem 287(6):4198-4210, 2012.
Huehls AM, Wagner JM, Huntoon CJ, Geng L, Erlichman C, Patel AG, Kaufmann SH, Karnitz LM. Poly(ADP-ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells. Cancer Res 71(14):4944-4954, 2011.
Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci USA 108(8):3406-3411, 2011.
Last update: August 2020